CEAPRO INC.
TSX VENTURE : CZO

CEAPRO INC.

January 17, 2007 09:00 ET

Ceapro Inc. announces investor relations appointment

EDMONTON, Jan. 17 - NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW.

Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Corporation")
today announced the appointment of Sun International
Communications to provide advisory services in financial communications and
investor relations with the objective of obtaining fair market valuation on
financial markets in 2007.

"We look forward to working with Sun International, especially Managing
Partner Ms. Nicole Blanchard, and developing Ceapro's profile," stated
Dr. Mark Redmond, Ceapro's President and CEO. "This association is critical in
light of the announcement of Ceapro's entry into the energy sector with the
incorporation of Ceapro BioEnergy, and the rounding out of our core business."

The managing partner of the group, Ms. Nicole Blanchard, is a bilingual
entrepreneurial manager with 20 years of experience in leading investor
relations positions for North American and European companies. She has managed
the investor relations program for large and small public companies, including
BioChem Pharma and Teleglobe, on Canadian, American, and European stock
exchanges. Her knowledge of North American and European financial markets and
her academic credentials in science and finance will be helpful to the
company's management team.

Subject to the approval of the TSX Venture Exchange, Ceapro has granted
100,000 options to Sun International Communications and a monthly retainer fee
of $5,000. Each of the options, which vest upon the Corporation achieving
certain performance and investment milestones, entitle the holder thereof to
acquire one (1) common share upon payment of the exercise price of $0.30 per
common share. Each option, upon vesting but subject to prior termination, is
exercisable for a period of five (5) years.

About Ceapro Inc.

Ceapro Inc is a Canadian growth stage biotechnology company. Ceapro's
core technology is the extraction of functional, active ingredients from
plants and other renewable resources. We add further value to our extracts by
manufacturing medical and therapeutic products, and by supporting the use of
our extracts in products for human and animal health. We have also introduced
health and wellness services employing our CeaProve® diagnostic technology.
Our most recent initiative is the creation of Ceapro BioEnergy Inc. (CBE), a
wholly-owned subsidiary to utilize Ceapro's proprietary technology for the
production of ethanol and value-added products. Ceapro shares trade on the
Canadian TSX Venture Exchange under the symbol CZO. To learn more about
Ceapro, visit our website at www.ceapro.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this news release.

This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements. Although the Company believes that the
forward-looking statements contained herein are reasonable, it can give no
assurance that the Company's expectations are correct. All forward-looking
statements are expressly qualified in their entirety by this cautionary
statement.

Contact Information

  • Dr. Mark Redmond, President and CEO, Ceapro
    Inc., Telephone (Edmonton): (780) 421-4555; Nicole Blanchard, B.Sc., B.Comm.,
    Managing Partner, Sun International Communications, Telephone (Montreal):
    (450) 627-6600